Care.Know.Do Pilot: Version 1

  • Research type

    Research Study

  • Full title

    Pilot evaluation of Care.Know.Do: a self-management intervention to support patients with chronic kidney disease.

  • IRAS ID

    184206

  • Contact name

    John Weinman

  • Contact email

    john.weinman@kcl.ac.uk

  • Sponsor organisation

    Atlantis Healthcare

  • Duration of Study in the UK

    1 years, 6 months, days

  • Research summary

    Research suggests that factors such as depression, lack of understanding of the relationship between high blood pressure, cardiovascular disease and kidney function, poor healthcare provider--patient communication and lack of social support can impact negatively on medication adherence and lifestyle modification in patients with CKD. Care.Know.Do aims to support CKD patients with these issues to achieve improved outcomes through improving self-management behaviours. This tailored, online patient support programme includes supplementary telephone calls and email/SMS messages, to support patients with CKD from the beginning of secondary care. The Care.Know.Do website will be integrated with (Renal) Patient View, a portal which gives patients direct access to their clinic test results. Care.Know.Do will pull key clinical data from Patient View, namely BP, eGFR, albumin:creatnine ration (ACR), and HbA1c to assess the Care.KnowDo’s impact on these clinical measures. Patients enrolling onto the programme will be asked to complete a screening questionnaire, so that the type of support they receive through the interventional channels can be tailored to their specific needs. The online programme includes three key modules to address: low mood (Mind Matters), lifestyle (Lifestyle Matters) and adherence to hypertension medication (Medication Matters). The aim of this exploratory study is to estimate the size of effect of the intervention and determine in which patient group this is the most significant, as well as test acceptability to patient and estimate ease of setting up and running a larger definitive trial. In addition to the screening questionnaire, patients will be asked to complete two follow up questionnaires to evaluate the effectiveness of the programme on patients self-management behaviours, their psychosocial well-being and illness/ treatment perceptions. A select group of patients and healthcare practioners will also be asked to participate in a qualitative interview to assess programme acceptability.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    15/LO/1700

  • Date of REC Opinion

    14 Dec 2015

  • REC opinion

    Further Information Favourable Opinion